NLM Publications / Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRAS/P53 Lung Cancer Cells by Inhibiting c-FLIP.
Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRAS/P53 Lung Cancer Cells by Inhibiting c-FLIP.